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NoOBJECTIVES This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients
with heart failure and reduced ejection fraction.
BACKGROUND Many patients with type 2 diabetes mellitus have heart failure and it is important to know about the
safety of new treatments for diabetes in these individuals.
METHODS Patients 18 to 85 years of age with type 2 diabetes and heart failure (New York Heart Association functional
class I to III and left ventricular ejection fraction [LVEF] <0.40) were randomized to 52 weeks treatment with vildagliptin
50 mg twice daily (50 mg once daily if treated with a sulfonylurea) or matching placebo. The primary endpoint was
between-treatment change from baseline in echocardiographic LVEF using a noninferiority margin of 3.5%.
RESULTS A total of 254 patients were randomly assigned to vildagliptin (n ¼ 128) or placebo (n ¼ 126). Baseline LVEF
was 30.6  6.8% in the vildagliptin group and 29.6  7.7% in the placebo group. The adjusted mean change in
LVEF was 4.95  1.25% in vildagliptin treated patients and 4.33  1.23% in placebo treated patients, a difference
of 0.62 (95% conﬁdence interval [CI]: 2.21 to 3.44; p ¼ 0.667). This difference met the predeﬁned noninferiority
margin of 3.5%. Left ventricular end-diastolic and end-systolic volumes increased more in the vildagliptin group by
17.1 ml (95% CI: 4.6 to 29.5 ml; p ¼ 0.007) and 9.4 ml (95% CI: 0.49 to 19.4 ml; p ¼ 0.062), respectively. Decrease in
hemoglobin A1c from baseline to 16 weeks, the main secondary endpoint, was greater in the vildagliptin
group: 0.62% (95% CI: 0.93 to 0.30%; p < 0.001; 6.8 mmol/mol; 95% CI: 10.2 to 3.3 mmol/mol).
CONCLUSIONS Compared with placebo, vildagliptin had no major effect on LVEF but did lead to an increase in
left ventricular volumes, the cause and clinical signiﬁcance of which is unknown. More evidence is needed regarding
the safety of dipeptidyl peptidase-4 inhibitors in patients with heart failure and left ventricular systolic dysfunction.
(Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure;
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AB BR E V I A T I O N S
AND ACRONYM S
BNP = B-type natriuretic
peptide
DPP = dipeptidyl peptidase
GLP = glucagon-like peptide
HFrEF = heart failure and
reduced ejection fraction
NYHA = New York Heart
Association
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9T ype 2 diabetes is common in patients withheart failure, with reported prevalences ofbetween 25% and 40% in trials and registries
(1–5). Heart failure patients with diabetes have worse
symptoms, greater functional limitation, and higher
rates of hospitalization and death than heart failure
patients without diabetes (1–5). The safety
of established treatments for diabetes in patients
with heart failure is uncertain. Sulfonylureas and in-
sulin can cause hypoglycemia and it has been thought
that metformin may increase the risk of lactic acidosis,
although this has never been demonstrated (6,7).
Thiazolidinediones increase the risk of patients
with diabetes developing heart failure (8,9). Thiazoli-
dinediones also increase the risk of worsening of heart
failure in patients with that condition (10,11).SEE PAGE 27Consequently, it is important that the safety of
new treatments for diabetes is studied in patients
with heart failure. One group of new treatments is
the dipeptidyl peptidase (DPP)-4 inhibitors, which
block the degradation of endogenous glucagon-like
peptide (GLP)-1 and glucose-dependent insulino-
tropic polypeptide (GIP), which stimulate insulin
secretion in a glucose-dependent manner, suppress
glucagon release, and slow gastric emptying (12–14).
Three recent large, randomized controlled trials have
reported conﬂicting evidence about the risk of heart
failure with different agents in this class (15–17).
None, however, characterized patients with heart
failure at baseline or those developing heart failure
during follow-up. Furthermore, none of the studies
examined the effect of a DPP-4 inhibitor on left
ventricular function. Here we report a study of the
effects of the DPP-4 inhibitor vildagliptin in patients
with heart failure and reduced ejection fraction
(HFrEF) (18,19).
METHODS
The VIVIDD (Vildagliptin in Ventricular Dysfunction
Diabetes) trial was a prospective, randomized,
double-blind, parallel-group trial comparing vilda-
gliptin with placebo, added to standard therapy for 52
weeks in patients with type 2 diabetes and HFrEF. An
ethics committee approved the trial at each site, and
patients provided written informed consent. PatientNovartis. Dr. Bolli is a consultant to and has been paid for giving lectures f
consultant for Novartis and Boehringer Ingelheim. All other authors have rep
contents of this paper to disclose. Dr. Krum is deceased.
Manuscript received May 14, 2017; revised manuscript received August 1, 20safety was reviewed by an independent
committee throughout the trial and cardio-
vascular, hepatic, and cutaneous (including
suspected angioedema) adverse events were
adjudicated by independent and masked
committees. All echocardiographic analyzes
were carried out by blinded assessors in a
core laboratory (Perceptive Informatics Inc.,
Billerica, Massachusetts). The study results
were analyzed by Novartis and conﬁrmed
by (J.L.) an independent statistician at the
University of Glasgow.
PARTICIPANTS. Brieﬂy, men and women between 18
and 85 years of age with type 2 diabetes (hemoglobin
A1c: 6.5% to 10.0% [48.0 to 86.0 mmol/mol]), body
mass index ranging from 22 to 42 kg/m2, heart failure
with a reduced ejection fraction (<40%), and in New
York Heart Association (NYHA) functional class I to III
were eligible. The key exclusion criteria were NYHA
functional class IV, a fasting plasma glucose concen-
tration of $15 mmol/l, receiving thiazolidinedione or
incretin therapy, a recent cardiovascular event
or procedure, creatinine clearance of <30 ml/min,
and liver disease or elevated transaminases or
bilirubin.
RANDOMIZATION AND MASKING. Eligible patients
were randomly assigned in a 1:1 ratio according to a
central randomization scheme, stratiﬁed by NYHA
functional class, to 1 of 2 treatment groups:
vildagliptin, 50 mg twice daily (50 mg once daily
if concomitant treatment with a sulfonylurea) or
placebo. Randomization was conducted using an
interactive voice response system. Vildagliptin and
placebo were identical in packaging, labelling,
appearance, and schedule of administration.
PROCEDURES. From May 4, 2009 (Figure 1), subjects
who met the inclusion/exclusion criteria (including
echocardiographic criteria) at the screening visit
entered a 2- to 4-week run-in period during which
the individuals continued their usual diet, exercise
regimen, and drug therapy for diabetes (if taking
drug therapy). Patients completing this period
returned for baseline assessment including mea-
surement of B-type natriuretic peptide (BNP) and
were then randomized to vildagliptin or placebo as
described above. Patients were examined every
4 weeks up to week 24 and every 8 weeks thereafteror Sanoﬁ-Aventis and Menarini. Dr. Ponikowski is a
orted that they have no relationships relevant to the
17, accepted August 3, 2017.
FIGURE 1 Study Timeline
DPP ¼ dipeptidyl peptidase; EXAMINE ¼ Examination of Cardiovascular Outcomes With Alogliptin vs Standard of Care; SAVOR-TIMI 53 ¼
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis In Myocardial Infarction 53;
TECOS ¼ Trial Evaluating Cardiovascular Outcomes With Sitagliptin; VIVIDD ¼ Vildagliptin in Ventricular Dysfunction Diabetes trial.
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10(diabetes “rescue” therapy could be used from week
16 onward). Repeat BNP measurements and echo-
cardiography were performed at 24 and 52 weeks.
Patients who permanently stopped treatment
before 52 weeks were asked to return for a ﬁnal
assessment, including an echocardiogram and BNP
measurement. Factors of NYHA functional class,
dyspnea, and edema were evaluated at baseline and
at each of the follow-up visits, as was blood chem-
istry (including hemoglobin A1c) and hematological
measurements.
ECHOCARDIOGRAPHY. Each echocardiogram was
analyzed by a minimum of 2 qualiﬁed echocardiog-
raphers blinded to treatment assignment and accord-
ing to a pre-speciﬁed protocol. The Simpson biplane
method of discs was used to calculate LVEF (20).
B-TYPE NATRIURETIC PEPTIDE. B-type natriuretic
peptide was measured using a triage Beckman
Coulter immunoassay (Covance Central Laboratory,
Princeton, New Jersey).
STUDY OBJECTIVES. This was a safety study. The
primary objective was to show that vildagliptin was at
least noninferior to placebo with respect to change in
LVEF from baseline to end of study. Recognizing that
not all patients would complete the planned
maximum of 52 weeks of treatment and that an effect
of drugs on left ventricular remodeling may be
apparent within 6 months, the original protocol was
altered during the trial (but before any resultswere known) to deﬁne the primary analysis of LVEF to
include any patient who had at least 1 follow-up
echocardiogram recorded 22 weeks or more after
randomization. The key secondary endpoint consisted
of a change in hemoglobin A1c from baseline to
16 weeks (with censoring for use of rescue therapy
before that time point).
SAFETY ASSESSMENTS. In addition to conventional
adverse event reporting, speciﬁc safety assessments
were made including assessment of NYHA functional
class and breathlessness and edema at each study
visit and adjudication of suspected worsening heart
failure symptoms (Online Table 1), and possible
cardiovascular, liver, and cutaneous events, as well as
deaths, by the adjudication committees described
above.
STATISTICAL ANALYSIS. The study sample size was
calculated based upon 90% power and a 1-sided
signiﬁcance level of 0.025 to declare noninferiority
of vildagliptin compared with placebo for the effect
of treatment of LVEF, using a margin of 3.5% and an
expected difference between the 2 treatments of 0%.
The choice of the noninferiority margin was based on
clinical importance and prior use (10). The calculation
was performed using nQuery Advisor version 5.0
(Statsols, Cork, Ireland) and based on a LVEF 7%
(derived from prior trials). We calculated that a total
of 172 patients with at least 1 LVEF measurement
after randomization were required. The sample size
TABLE 1 Baseline Characteristics of Patients and Treatment
Vildagliptin
(n ¼ 128)
Placebo
(n ¼ 126)
Age, yrs 62.9  8.5 63.4  10.2
Females, 29 (22.7) 30 (23.8)
BMI, kg/m2 29.6  4.6 29.3  4.7
Obese, 54 (42.2) 50 (39.7)
Current smoker 21 (16.4) 9 (7.1)
Systolic blood pressure, mm Hg 130.4  16.3 127.9  15.3
Diastolic blood pressure, mm Hg 77.6  8.9 77.2  8.7
Heart rate, beats/min 73.1  10.1 73.5  9.3
History
Myocardial infarction 82 (64.1) 80 (63.5)
Angina pectoris 55 (43.0) 48 (38.1)
CABG 30 (23.4) 30 (23.8)
PCI 24 (18.8) 22 (17.5)
Stroke 12 (9.4) 11 (8.7)
Atrial ﬁbrillation 29 (22.7) 34 (27.0)
Hypertension 112 (87.5) 108 (85.7)
Prior hospitalization for HF 66 (51.6) 55 (43.7)
COPD 16 (12.5) 8 (6.3)
Diabetes status
Duration of diabetes, yrs 9.5  8.1 9.1  7.8
Hemoglobin A1c, %;
mmol/mol
7.8  0.95;
62.0  10.4
7.8  1.07;
62.0  11.7
Heart failure status
NYHA functional class
I 13 (10.2) 12 (9.5)
II 68 (53.1) 66 (52.4)
III 47 (36.7) 48 (38.1)
LVEF, % 30.6  6.8 29.6  7.7
LVEF, #35% 91 (71.1) 96 (76.2)
BNP, pg/ml 244 (133–558) 217 (113–430)
Treatment, %
ACE inhibitor 71.8 61.9
ARB 23.4 28.6
Beta-blocker 79.7 76.2
MRA 46.1 37.3
Digitalis glycoside 28.9 23.0
Diuretic (loop) 71.1 70.7
ICD 9.4 7.9
CRT 10.2 11.9
Insulin
Monotherapy 24.2 24.6
Any 35.2 33.3
Oral anti-diabetes therapy
Sulfonylurea 46.9 53.2
Metformin 36.7 32.5
AGI 0.8 3.2
Glinide 1.6 0
Any oral therapy 63.3 68.3
Diet only 12.5 7.1
Values are mean  SD, n (%), median (interquartile range), or %.
ACE ¼ angiotensin-converting enzyme; AGI ¼ alpha-glucosidase inhibitor;
ARB ¼ angiotensin receptor blocker; beats/min ¼ beats per minute; BMI ¼ body
mass index; BNP ¼ B-type natriuretic peptide; BP ¼ blood pressure; CABG ¼
coronary artery bypass grafting; CRT ¼ cardiac resynchronization therapy;
ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection
fraction; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart
Association; PCI ¼ percutaneous coronary intervention.
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11was inﬂated to 246 patients to allow for approxi-
mately 30% of patients not having an LVEF mea-
surement after randomization. An analysis of
covariance model (ANCOVA) was ﬁtted, including
terms for treatment, baseline LVEF, NYHA functional
class, and region. The least-square mean (LSM,
“adjusted mean”) change from baseline in LVEF was
calculated for each treatment group and the differ-
ence in LSM between the 2 treatment groups and the
2-sided 95% conﬁdence interval (CI) were obtained
from this model.
An ANCOVA model ﬁtted with terms for treatment,
baseline hemoglobin A1c, and region was used to
analyze LSM change in hemoglobin A1c. Other
exploratory variables were analyzed in a similar way
with appropriate transformations if the normality
assumption was questionable. The statistical software
used was SAS version 9.2 (Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS AND TREATMENT. A total
of 254 patients were randomized at 67 sites in 15
countries. Their mean age was 63 years of age, and 77%
were male. Other key demographic characteristics,
medical history, and treatment at baseline are shown
in Table 1. The ﬁrst patient visit was May 4, 2009, and
the last patient visit was August 13, 2012. Overall, pa-
tients had a mean duration of diabetes of 9.3 years
(median: 6.8 years), and the mean hemoglobin A1c at
baseline was 7.8% (62.0 mmol/mol); 34% of patients
were treated with metformin, and the same propor-
tion with insulin, either as monotherapy or in combi-
nation with other glucose-lowering agents. The
median duration of heart failure was 3.3 years, mean
left ventricular ejection fraction was 30%, median BNP
was 231 pg/ml, and most patients were in NYHA
functional class II (53%) or III (37%); 48% of patients
had a history of hospital admission for heart failure.
More than 90% of patients were treated with an
angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker; 78% with a beta-blocker; and
42% with a mineralocorticoid receptor antagonist.
Baseline characteristics between treatment groups
were well balanced, except that more patients in the
vildagliptin treatment group had a history of smoking,
prior hospitalization for heart failure, or chronic
obstructive pulmonary disease.
FOLLOW-UP AND ADHERENCE. Overall, 101 patients
(79%) assigned to vildagliptin and 100 patients (79%)
assigned to placebo completed the 52-week follow-up
as planned (Figure 2). There were 11 deaths (8.6%)
in the vildagliptin group and 4 deaths (3.2%) in the
FIGURE 2 Flow Chart of Participants
TABLE 2 Baseline Echocardiographic Measurements
Vildagliptin
(n ¼ 128*)
Placebo
(n ¼ 126*)
LVIDD, cm† 5.9  0.91 5.9  0.93
LVISD, cm† 5.2  0.93 5.2  0.91
LVEDV, ml* 179  59 168  66
LVESV, ml* 125  44 120  56
LVSV, ml 54.3  21.0 48.1  18.3
LVEF, % 30.6  6.8 29.6  7.7
LV-SWT, cm 1.0  0.24 1.0  0.25
LV-PWT, cm 1.0  0.20 1.0  0.21
LVMi, g/m2 134  39 130  41
Values are mean  SD. *Not all measurements were obtained in every patient.
†LVEDVi ¼ 92 ml/m2; LVESVi ¼ 65 ml/m2.
LVEDV ¼ left ventricular end diastolic volume; LVEDVi ¼ left ventricular end
diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left
ventricular end systolic volume; LVESVi ¼ left ventricular end systolic volume
index; LVIDD ¼ left ventricular internal diastolic dimension; LVISD ¼ left
ventricular internal systolic dimension; LVMi ¼ left ventricular mass index;
LV-PWT ¼ left ventricular posterior wall thickness; LVSV ¼ left ventricular stroke
volume; LV-SWT ¼ left ventricular septal wall thickness.
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12placebo group. Other reasons for not completing
follow-up were adverse events (5 vildagliptin vs. 4
placebo), withdrawal of consent (3 vs. 10), protocol
violation (3 vs. 2), loss to follow-up (2 vs. 2), unsatis-
factory therapeutic effect (2 vs. 1), and administrative
problems (1 vs. 3). Overall, 16 patients (12.5%) assigned
to vildagliptin and 22 patients (17.4%) assigned to
placebo discontinued study drug early for reasons
other than death.
PRIMARY ENDPOINT: CHANGE IN LVEF. The LVEF
was matched between treatment groups at baseline
(Table 2). The intention to treat analysis is shown
in Figure 3. The pre-speciﬁed primary analysis
(patients with a baseline and follow-up measurement
of LVEF $22 weeks) included 89 patients assigned
to vildagliptin (mean baseline LVEF of 30.5  0.67%)
and 90 assigned to placebo (29.8  0.78%). The
adjustedmean change in LVEFwas 4.95 1.25%) in the
vildagliptin group and 4.33% ( SE 1.23%) in the pla-
cebo group; a difference of 0.62% (95% CI: 2.21
to 3.44; p ¼ 0.667). This difference met the predeﬁned
noninferiority criterion of 3.5% at p value of
0.025. Examination of the patients (88 vildagliptin,
89 placebo) with a 48-week follow-upmeasurement ofLVEF gave almost identical ﬁndings (for sensitivity
analyses see Online Table 2).
OTHER ECHOCARDIOGRAPHIC FINDINGS. Changes in left
ventricular volumes are shown in Table 2 and Figure 3.
Left ventricular end-diastolic volume increased
FIGURE 3 Change From Baseline in LVEF (Primary Endpoint) and Other Echocardiographic Measurements
(A) Change in LVEF (%). Differences in adjusted mean change 0.62 (95% CI: 2.21 to 3.44; p ¼ 0.667)*. *Meets criteria for noninferiority to
comparator as the lower limit of the 2-sided 95% CI for the differences in mean change in LVEF is >3.5%. Primary analysis is based on per
protocol. (B) Change in LVEDV (ml). Differences in adjusted mean change 17.06 (95% CI: 4.62 to 29.51; p ¼ 0.007). Full analysis set. (C)
Change in LVESV. Differences in adjusted mean change 9.44 (95% CI: 0.49 to 19.38; p ¼ 0.062). Full analysis set. (D) Change in the LVSV.
Difference in adjusted mean change 9.00 (95% CI: 3.38 to 14.62; p ¼ 0.002). Full analysis set. CI ¼ conﬁdence interval; LVEF ¼ left
ventricular ejection fraction; LVESV ¼ left ventricular end systolic volume; LVSV ¼ left ventricular stroke volume.
TABLE 3 Nonfatal Cardiovascular Events and Deaths
Vildagliptin
(n ¼ 128)
Placebo
(n ¼ 126)
Rate Difference,
% (95% CI)
Any fatal or nonfatal
cardiovascular event*
35 (27.3) 31 (24.6) 2.7 (9.5 to 15.0)
Death from cardiovascular causes 7 (5.5) 4 (3.2) 2.3 (10.3 to 14.6)
Worsening heart failure 23 (18.0) 22 (17.5) 0.5 (11.9 to 12.7)
Acute coronary syndrome 7 (5.5) 3 (2.4) 3.1 (9.5 to 15.4)
Cardiac arrhythmia 9 (7.0) 4 (3.2) 3.9 (8.7 to 16.1)
Stroke 1 (0.8) 4 (3.2) 2.4 (14.9 to 10.1)
Death from any cause 11 (8.6) 4 (3.2) 5.4 (7.2 to 17.6)
Values are n (%). *Patients were counted only once, even if there were multiple events. There
were 4 noncardiovascular deaths in the vildagliptin group, resulting from hepatic neoplasm, lung
neoplasm, septic shock, and surgery for intestinal obstruction due to peritoneal adhesions.
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13signiﬁcantly with vildagliptin compared with pla-
cebo, and there was a trend in the same direction for
end-systolic volume which was of borderline statis-
tical signiﬁcance (6- and 12-month volumes are
shown in Online Table 3). There was a signiﬁcant
increase in stroke volume but no change in left
ventricular wall thickness or mass.
SECONDARY ENDPOINT: CHANGE IN HEMOGLOBIN A1C.
The adjusted mean change from baseline to rescue-
censored week 16 hemoglobin A1c was 0.45 
0.12% (4.9  1.3 mmol/mol) in the vildagliptin
group and 0.17  0.12% (1.9  1.3 mmol/mol) in the
placebo group, with an adjusted mean difference
(vildagliptin  placebo) of 0.62% (95% CI: 0.93 to
0.30%; p < 0.001; 6.8 mmol/mol; 95% CI: 10.2
to 3.3 mmol/mol). The difference at week 52
was 0.36% (95% CI: 0.71 to 0.02%; p ¼ 0.040;
3.9 mmol/mol; 95% CI: 7.8 to 0.2 mmol/mol).
CHANGE IN BNP. Baseline geometric mean BNP values
for those with an end of study measurement were227 pg/ml in patients assigned to vildagliptin and 214
pg/ml in those assigned to placebo. A reduction
in geometric mean BNP values from baseline was
observed in both treatment groups: ratio of 52 weeks/
baseline: 0.72 (95% CI: 0.56 to 0.93) in the vildagliptin
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14group (n ¼ 75) and 0.86 (95% CI: 0.67 to 1.12) in the
placebo group (n¼ 81). The ratio of ratios (vildagliptin/
placebo) was 0.84 (95% CI: 0.62 to 1.14; p ¼ 0.252).
OTHER MEASUREMENTS OF HEART FAILURE
STATUS. Changes in dyspnea and edema from
baseline over the course of the study were small and
did not differ between treatment groups. There was
no difference in change in NYHA functional class
distribution between the 2 treatment groups, and the
proportion of patients with an increase in heart failure
medication during the study was 26.6% in the
vildagliptin group and 24% in the placebo group
(p ¼ 0.640). Speciﬁcally, the proportion of patients
taking loop diuretics at baseline was 64.8% and
65.9% of patients in the vildagliptin and the placebo
groups, respectively, and increased during the study
to 71.1% and 72.2%, respectively. Worsening heart
failure (including hospitalization for heart failure) was
conﬁrmed by the endpoint committee in 23 patients
(18.0%) in the vildagliptin group and 22 patients
(17.6%) in the placebo group; the number of
episodes of worsening was 39 versus 33, respectively
(Online Table 4). Hospital admissions for heart
failure were reported in 13 patients (10.2%) in the
vildagliptin group and 10 patients (8.0%) in
the placebo group (p ¼ 0.552).
OTHER ADJUDICATED CARDIOVASCULAR EVENTS,
HEPATICEVENTS,ANDDEATHS. Overall, 19 vildagliptin-
treated patients (14.8%) and 14 placebo patients
(11.2%) were admitted to the hospital for a cardio-
vascular cause (Table 3). In addition to heart failure
(see above), these causes included acute coronary
syndrome (6.3% vs. 0.8%, respectively) and a cardiac
arrhythmia (3.9% vs. 1.6%, respectively).
Atrial ﬁbrillation was detected on analysis of
electrocardiograms in 6 vildagliptin-treated and
0 placebo-treated patients. Of the 11 deaths in the
vildagliptin group, 7 were attributed to cardiovascular
causes (Table 3) (5 to cardiorespiratory arrest or sud-
den death and 2 to myocardial ischemia or infarction),
2 to cancer, 1 to infection, and 1 to intestinal obstruc-
tion. All 4 deaths in the placebo group were attributed
to cardiovascular causes.
OTHER ADVERSE EVENTS. Reports of hypoglycemia
were similar in the 2 treatment groups (4.7% with
vildagliptin vs. 5.6% with placebo). Two hepatic
adverse events were conﬁrmed on adjudication,
both in the vildagliptin group. One event was a case
of cirrhosis and the other jaundice secondary
to hepatocellular carcinoma, but neither was
considered drug-related. No predeﬁned signiﬁcant
elevations in transaminases or bilirubin occurred
in either treatment group. One patient in thevildagliptin group died from hepatic cancer.
No cases of pancreatitis were reported. There were
no cases of angioedema conﬁrmed by the adjudica-
tion committee.
OTHER FINDINGS. There were no signiﬁcant differ-
ences between treatment groups for change from
baseline to end of study in weight, heart rate, blood
pressure, estimated glomerular ﬁltration rate, or
urinary albumin-to-creatinine ratio.
DISCUSSION
The primary goal of this safety study was to compare
the effect of vildagliptin, 50 mg twice daily, with
that of placebo, added to conventional treatment
for diabetes, on LVEF in patients with HFrEF.
The study met the pre-speciﬁed objective of showing
noninferiority, that is, it showed that vildagliptin,
compared with placebo, did not cause a major reduc-
tion in LVEF. Indeed, mean LVEF increased slightly
from baseline in each treatment group. Two other
ﬁndings, however, were unexpected and merit
comment. First, we showed that left ventricular
volumes increased with vildagliptin treatment, and
second, there were more deaths in the vildagliptin
group than in the placebo group.
The increase in left ventricular volumes is hard
to explain and could reﬂect baseline imbalances
(see Results) or the play of chance. Baseline end-
diastolic volume was higher in the vildagliptin
group, as was BNP concentration and the percentage
of patients with prior hospitalization for HF,
suggesting that the patients in this group might have
also been more susceptible to adverse left ventricular
remodeling. However, if vildagliptin induced adverse
left ventricular remodeling, a decline in LVEF and a
rise in BNP would have been expected. Instead,
we observed a slightly greater increase in LVEF and a
trend to a greater reduction in BNP in the vildagliptin
group, although neither trend was signiﬁcant.
Similarly, adverse remodeling might also have been
reﬂected in evidence of worsening heart failure,
which was not seen.
On the other hand, the potentially harmful
consequences of left ventricular enlargement, if real,
cannot be ignored. Increase in left ventricular volume
is associated with worse clinical outcomes, including
mortality, in heart failure (21,22). This draws atten-
tion to the second surprising observation in the
present study, which was of a higher mortality rate in
the vildagliptin group. However, the total number
of deaths was small and the imbalance in deaths
attributable to a cardiovascular-cause death was
7 versus 4 (with none in the vildagliptin group
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15attributed to worsening heart failure), respectively.
We believe, therefore, this imbalance most likely
reﬂects the play of chance.
However, it is not certain that all DPP-4 inhibitors
are safe in patients with heart failure. In the
SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients With Diabetes
Mellitus-Thrombolysis In Myocardial Infarction 53)
trial, the DPP-4 inhibitor studied led to a signiﬁcant
increase in risk of hospitalization for heart failure
(289 vs. 228 patients, respectively; p ¼ 0.007) (12,16).
Treatment with a different DPP-4 inhibitor in the
EXAMINE (Examination of Cardiovascular Outcomes
With Alogliptin vs Standard of Care) trial also
led to a higher rate of hospitalization for heart
failure, although the difference from placebo was
not statistically signiﬁcant (106 vs. 89 patients,
respectively; p ¼ 0.22) (13,17). Conversely, there was
no suggestion of an increased risk of heart failure
hospitalization (228 vs. 229 patients, respectively;
p ¼ 0.95) in the TECOS (Trial Evaluating Cardiovas-
cular Outcomes With Sitagliptin) study (14,15). It
should be noted that the above-mentioned trials
were not conducted speciﬁcally in patients with
heart failure and that the minority of patients
with heart failure at baseline in those trials were not
phenotyped according to left ventricular function
(and nor were those hospitalized during follow-up)
(15,17). The VIVIDD trial was quite different in
testing the effects of a DPP-4 inhibitor in patients
with established heart failure and documented
reduced LVEF. While heart failure-related hospitali-
zations did not occur more frequently with
vildagliptin (13 vs. 10 events, respectively; p ¼ 0.55)
in the present study, our trial was small and was not
powered to detect differences in clinical outcomes.
Consequently, we could have missed a safety signal
in VIVIDD. Indeed, in a trial very similar to the
present one in terms of design and size assessing the
thiazolidinedione rosiglitazone in patients with
systolic heart failure, the difference between
rosiglitazone and placebo in change in LVEF from
baseline was 1.49 (95% CI: 0.32 to 3.30; p ¼ 0.10),
fulﬁlling noninferiority according to the same crite-
rion used in the present trial (11). Rosiglitazone did
not increase left ventricular volumes (although it did
raise BNP) (11). Despite this, it is clear that glitazones
increase the risk of developing heart failure and the
risk of worsening in patients with heart failure (8,9).
Consequently, although all of the concerning ﬁnd-
ings in the various DPP-4 inhibitor trials described
above may be due to chance and unrelated, the
possibility exists that these drugs could have
adverse effects on myocardial structure andfunction. In relation to this, it is also worth exam-
ining the GLP-1 receptor agonist trials which used
agents sharing a similar (but not identical) mecha-
nism of action to that of the DPP-4 inhibitors. In 3
large trials including patients largely free of heart
failure at baseline, lixisenatide, liraglutide, and
semaglutide had a neutral effect on heart failure
outcomes (23–25). However, in two small studies in
patients with established HFrEF, there was the sug-
gestion (but not deﬁnitive evidence) that treatment
with liraglutide might have led to worse outcomes
than placebo (26,27). In animal studies of myocardial
infarction, DDP-4 inhibitors (including vildagliptin)
have shown either a neutral or favorable effect on
left ventricular remodeling (28–30).
STUDY LIMITATIONS. Inevitably, the present study
has limitations. Although sufﬁciently powered
to evaluate the primary endpoint, it was still a
relatively small trial and was not powered to
robustly assess clinical outcomes. There was a
small difference in baseline left ventricular volumes
that could have inﬂuenced subsequent changes in
these measurements. The rate of discontinuation
was relatively high (Figure 2), and only 70% of
patients who completed the study according to
protocol without major protocol deviations had at
least 1 follow-up echocardiogram 22 or more weeks
after randomization, although the number of
patients with at least 2 analyzable echocardiograms
was more than needed according to our power
calculations.
CONCLUSIONS
Although the present study showed that vildagliptin
was noninferior to placebo with respect to change
in LVEF, it did show that use of this DPP-4 inhibitor
was associated with an increase in left ventricular
volumes. However, there was no increase in BNP
or any other indication of worsening heart failure
status. Whether the increase in ventricular volumes
indicates some unexplained action of vildagliptin
on left ventricular remodeling or a chance ﬁnding
is unknown, as are its clinical implications. More
evidence is needed regarding the safety of DPP-4
inhibitors in patients with established heart failure
and left ventricular systolic dysfunction.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:While it is
now accepted that the cardiovascular safety of new
glucose-lowering treatments for type 2 diabetes must be
demonstrated before marketing, there is no speciﬁc
requirement to show safety in patients with HFrEF. This is
despite evidence that at least 1 class of hypoglycemic
drugs, the thiazolidinediones, can lead to the worsening of
heart failure. We studied the safety of the dipeptidyl
peptidase-4 inhibitor, vildagliptin, in patients with type 2
diabetes and HFrEF by measuring change in LVEF over
52 weeks. Although vildagliptin, compared with placebo,
met the prespeciﬁed noninferiority margin for safety,
vildagliptin led to an unexpected and unexplained increase
in left ventricular volumes.
TRANSLATIONAL OUTLOOK: While the clinical
signiﬁcance of our ﬁndings is unknown, there are other
data with an agent in the same class, saxagliptin, showing
an increase in risk of incident heart failure hospitalization.
While both sets of results may reﬂect the play of chance,
they do, along with the earlier thiazolidinedione
ﬁndings, highlight the need to examine the safety of new
glucose-lowering treatments speciﬁcally in patients
with diabetes and HFrEF who are a particularly high risk
and vulnerable group.
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